Re: Adjuvant Atezolizumab Versus Placebo for Patients with Renal Cell Carcinoma at Increased Risk of Recurrence Following Resection (IMmotion010): A Multicentre, Randomised, Double-blind, Phase 3 Trial

Eur Urol. 2023 Mar;83(3):297-298. doi: 10.1016/j.eururo.2022.11.010. Epub 2022 Dec 1.

Authors

Zhenjie Wu¹, Linhui Wang¹, Savio D Pandolfo², Riccardo Autorino³

Affiliations

¹ Department of Urology, Shanghai Changhai Hospital, Naval Medical University, Shanghai, China.
² Department of Neurosciences, Reproductive Sciences and Odontostomatology, University of Naples Federico II, Naples, Italy.
³ Department of Urology, Rush University Medical Center, Chicago, IL, USA. Electronic address: ricautor@gmail.com.

PMID: 36464531
DOI: 10.1016/j.eururo.2022.11.010

No abstract available

Publication types

Randomized Controlled Trial
Multicenter Study
Clinical Trial, Phase III
Comment

MeSH terms

Adjuvants, Immunologic / therapeutic use
Antibodies, Monoclonal, Humanized / adverse effects
Antineoplastic Agents* / therapeutic use
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Carcinoma, Renal Cell* / drug therapy
Carcinoma, Renal Cell* / surgery
Double-Blind Method
Humans
Kidney Neoplasms* / drug therapy
Kidney Neoplasms* / surgery

Substances

atezolizumab
Antineoplastic Agents
Antibodies, Monoclonal, Humanized
Adjuvants, Immunologic